Story · Medicine & Biotech

FDA OKs First Drug for Primary Membranous Nephropathy

2 outlets · first reported by FDA Drug Safety / Drugs feed on · latest · 64 hours of coverage

(MedPage Today) -- The FDA has once again expanded the label for the B-cell depleter obinutuzumab (Gazyva), this time to include treatment of primary membranous nephropathy. The new indication, announced by the agency on Friday, stipulates use... (MedPage Today)

Coverage, in order

  1. FDA Approves First Drug to Treat Adults with Primary Membranous Nephropathy

    FDA approved Gazyva (obinutuzumab) injection to induce remission of proteinuria (protein in the urine) in adults with primary membranous nephropathy at risk of disease progression.

  2. FDA OKs First Drug for Primary Membranous Nephropathy

    (MedPage Today) -- The FDA has once again expanded the label for the B-cell depleter obinutuzumab (Gazyva), this time to include treatment of primary membranous nephropathy. The new indication, announced by the agency on Friday, stipulates use...

Alivewire groups outlets reporting the same story. Each headline links to the outlet that wrote it; nothing is republished here.